Balancing the Benefits and Risks of Inhaled Long-Acting Beta-Agonists — The Influence of Values

Artigo que traz algum contributo para a controvérsia e levanta a questão da necessidade de atitudes reguladoras por parte da FDA no sentido da proibição do uso de LABA isolados no tratamento da Asma.

In December 2008, the Food and Drug Administration (FDA) convened a joint meeting of the Pediatric Advisory Committee, the Pulmonary–Allergy Drugs Advisory Committee, and the Drug Safety and Risk Management Advisory Committee (of which I am a member) to review the risks and benefits of inhaled long-acting beta-agonists (LABAs) for the treatment of asthma in adults and children. Committee members were asked to weigh the public health implications of real and serious but relatively infrequent occurrences of severe asthma exacerbations and asthma-related death against the symptomatic benefits of bronchodilation and asthma control. The drugs in question included single-agent LABA products . . .

Kramer JM. Balancing the Benefits and Risks of Inhaled Long-Acting Beta-Agonists — The Influence of Values. N Engl J Med 2009;360:1592-1595

http://content.nejm.org/cgi/reprint/360/16/1592.pdf

Ler também o editorial do NEJM

Drazen, J. M., O'Byrne, P. M. (2009). Risks of Long-Acting Beta-Agonists in Achieving Asthma Control. NEJM 360: 1671-1672. http://content.nejm.org/cgi/reprint/360/16/1671.pdf